Press Releases

Date Title
May 5, 2021 Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia
Pre-validation study demonstrates commercial laboratory systems readiness; data show strong performance consistent with verification study SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing
May 4, 2021 Survey Reveals Pregnant Women Lack Awareness About Preeclampsia, the #2 Cause of Maternal Death
Progenity survey shows more women know their baby’s “fruit size” than the key indicator of a common pregnancy complication Preeclampsia Awareness Month aims to educate women about the potentially deadly condition and recent advancements in diagnostic risk assessment SAN DIEGO, May 04, 2021 (GLOBE
April 30, 2021 Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Data demonstrate strong sensitivity and negative predictive value (NPV) SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced
April 26, 2021 Progenity to Present Two Abstracts for Novel Ingestible Drug Delivery Technologies at Digestive Disease Week 2021
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that two abstracts related to Progenity’s ingestible drug delivery
April 8, 2021 Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women’s health, will be presenting verification study data for its Preecludia™ rule-out
April 6, 2021 Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted
March 18, 2021 Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M in gross proceeds from a recent private placement with two leading healthcare-focused investment
March 12, 2021 Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report fourth quarter and full year 2020 financial results on
February 23, 2021 Progenity Announces $25 Million Private Placement
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it has entered into a definitive securities purchase
February 17, 2021 Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced the initiation of a clinical study for their Drug Delivery System (DDS)
Displaying 11 - 20 of 74